Salud financiera de hoja de balance de Passage Bio
Salud financiera controles de criterios 6/6
Passage Bio tiene un patrimonio de los accionistas total de $104.9M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $140.5M y $35.6M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$104.53m |
| Patrimonio | US$104.88m |
| Total pasivo | US$35.65m |
| Activos totales | US$140.53m |
Actualizaciones recientes sobre salud financiera
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Jun 11
We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate
Feb 27Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Nov 13We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully
Jun 23Recent updates
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Jun 11We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate
Feb 27Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Nov 13We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully
Jun 23Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Nov 13Passage appoints William Chou CEO
Oct 10Passage Bio GAAP EPS of -$0.73 beats by $0.09
Aug 04We're A Little Worried About Passage Bio's (NASDAQ:PASG) Cash Burn Rate
Jun 03Passage Bio: Worth Keeping An Eye On
Apr 11Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?
Dec 15Passage Bio (NASDAQ:PASG) Is In A Good Position To Deliver On Growth Plans
Aug 19Passage Bio: Price Reduced, But Without Data, Does Not Look Convincing
Jun 06Passage Bio partners with InformedDNA to offer counseling, testing for early dementia
May 03We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely
Mar 08Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?
Feb 01
Passage Bio on go with PBGM01 gene therapy trial in the U.S.
Jan 04Need To Know: Passage Bio, Inc. (NASDAQ:PASG) Insiders Have Been Buying Shares
Dec 28U.K. authorizes Passage Bio's PBGM01 trial
Dec 10Passage Bio (PASG) Investor Presentation - Slideshow
Nov 16Passage Bio EPS beats by $0.13
Nov 10Passage Bio’s PBKR03 nabs Orphan drug tag and accelerated review status for Krabbe disease
Oct 28Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($118.0M) de PASG superan a sus pasivos a corto plazo ($16.3M).
Pasivo a largo plazo: Los activos a corto plazo de PASG ($118.0M) superan a sus pasivos a largo plazo ($22.9M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: PASG está libre de deudas.
Reducción de la deuda: PASG no ha tenido ninguna deuda en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: PASG tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: PASG dispone de suficiente cash runway para 1.2 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 17.3% cada año.